STOCK TITAN

Teleflex Incorporated - TFX STOCK NEWS

Welcome to our dedicated page for Teleflex Incorporated news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex Incorporated stock.

Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.

The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.

Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.

The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.

Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.

In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.

Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.

For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.

Rhea-AI Summary
Teleflex Incorporated announces acquisition of Palette Life Sciences AB for $600 million, expanding its Interventional Urology portfolio. The acquisition includes the biodegradable rectal spacer Barrigel®, which reduces radiation during prostate cancer therapy. The transaction is expected to be completed in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
-
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) announced three group purchasing agreements with Premier, Inc. for select medical products, allowing Premier members to access special pricing and terms for Laryngoscope Systems, Laryngeal Masks Airways, and Disposable Anesthesia Products. The agreements aim to provide healthcare providers with solutions to optimize patient outcomes and improve care quality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
Rhea-AI Summary
Teleflex Incorporated (NYSE:TFX) will host a conference call on August 3, 2023, to discuss its second quarter financial results and provide an operational update. Participants can pre-register and receive dial-in information. The call will be accessible via live audio webcast on teleflex.com. An audio replay will be available on the company's website or by telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) completes patient enrollment in the Ringer™ PTCA study, evaluating the performance of the Ringer™ Perfusion Balloon Catheter in patients undergoing Percutaneous Coronary Interventions. The study, led by Principal Investigator Kathleen Kearney M.D., aims to validate the device's clinical efficacy and regulatory pathway for release. Completion of enrollment marks a significant milestone in the development of the Ringer™ Perfusion Balloon Catheter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none

FAQ

What is the current stock price of Teleflex Incorporated (TFX)?

The current stock price of Teleflex Incorporated (TFX) is $190.64 as of November 21, 2024.

What is the market cap of Teleflex Incorporated (TFX)?

The market cap of Teleflex Incorporated (TFX) is approximately 8.8B.

What does Teleflex Incorporated do?

Teleflex Incorporated is a global provider of specialty medical devices for critical care and surgical procedures, serving healthcare providers in over 150 countries.

Where is Teleflex Incorporated headquartered?

Teleflex Incorporated is headquartered in Wayne, Pennsylvania, USA.

How many people does Teleflex employ?

Teleflex employs approximately 12,000 people worldwide.

What are the main segments of Teleflex's business?

Teleflex operates in seven main segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and other.

What percentage of Teleflex’s revenue comes from the United States?

About 60% of Teleflex’s revenue comes from the United States.

What recent acquisitions has Teleflex made?

Teleflex recently acquired Palette Life Sciences AB to bolster its portfolio and operational efficiencies.

What is the UroLift™ System?

The UroLift™ System is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that helps preserve patient quality of life.

What was Teleflex's revenue growth in 2023?

Teleflex achieved a 6.5% constant currency revenue growth in 2023.

How can one access Teleflex's investor conference calls?

Teleflex's investor conference calls can be accessed via a live audio webcast on their website, teleflex.com.

What is the mission of Teleflex Incorporated?

Teleflex's mission is to provide solutions that improve outcomes and enhance safety for patients and healthcare providers.

Teleflex Incorporated

NYSE:TFX

TFX Rankings

TFX Stock Data

8.83B
46.31M
0.28%
99.65%
1.42%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
WAYNE